

Special Issue

Tumor-Associated Antigens in Therapeutic Development

Message from the Guest Editor

Over the last few decades, there has been immense progress in immunotherapy for different cancer types. In this regard, the development of cancer vaccines was conceptualized as therapeutics leading activation of long-lasting immune memory. Since then, many novel and specific targets have emerged for different cancers. These include tumor-specific antigens or neoantigens, oncogenic viral antigens and cancer germline antigens. Neoantigens are cancer-specific and result from somatic mutations on the tumor-cell surface, while cancer germline antigens are inherited mutations in genes which predispose an individual to cancer. Finally, viruses that produce oncogenic effects in the host are oncogenic viral antigens. This Special Issue will discuss the discovery of these targets and development of therapeutics against them.

Guest Editor

Dr. Divya Ramchandani
Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY 10065,
USA

Deadline for manuscript submissions

closed (31 October 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/121588

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).